Navigation Links
AcuNetx Announces Change in Trading Status
Date:9/3/2010

TORRANCE, Calif., Sept. 3 /PRNewswire/ -- AcuNetx, Inc. (OTC Bulletin Board: ANTXE) today announced that it had received a communication from the Financial Industry Regulatory Authority (FINRA) to the effect that its Common Stock would be removed from quotation on the OTC Bulletin Board on September 3, 2010.

The letter indicated that FINRA took the action because AcuNetx has been delinquent in its filings under the Exchange Act three times in the past two years, and NASD Rule 6530 provides for removal from quotation in this instance. AcuNetx has the right to appeal the decision, and is considering whether to file such an appeal.

Robert S. Corrigan, President of AcuNetx, said, "We plan to continue filing reports and financial statements with the SEC, and we expect that our stock will continue to be quoted and traded in the over-the counter market (Pink Sheets)." He added, "Accordingly, we believe this action will not have any effect on our shareholders, and should have no effect on the liquidity of our Common Stock."

Corrigan explained that AcuNetx had timely filed its 10-Q for the quarter ended June 30, 2010. However, since AcuNetx had earlier dismissed its independent certified public accountants and has not engaged new accountants, the financial statements in the 10-Q were not reviewed by outside accountants, as contemplated by SEC accounting rules. FINRA took the position that, because of this, the filing was deficient.

"We are actively interviewing accounting firms, and plan to retain a new firm in the coming weeks," said Corrigan. "Once retained, we will ask the new accountants to review our current 10-Q filings and amend them if necessary."

About AcuNetx, Inc.:

AcuNetx markets a diverse line of diagnostic, analytical and therapeutic tools for medical (audiologists, neurologists, otolaryngologists and physical therapists as well as hospitals, clinics, and extended care facilities) and law enforcement applications. R&D applications include patent-pending technology for the physiological detection of deception (polygraph). AcuNetx is headquartered in Torrance, CA. For more information concerning AcuNetx and its subsidiaries, please visit www.acunetx.com.

Safe Harbor for Forward Looking Statements:

This news release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements represent management's opinion. While management believes such representations to be accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risks and uncertainties. Important factors that may cause actual results to differ are set forth in the company's periodic filings with the U.S. Securities and Exchange Commission. FOR FURTHER INFORMATION CONTACT:Name:  Robert CorriganE-Mail:  rscorrigan@acunetx.com
'/>"/>

SOURCE AcuNetx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... PHOENIX , March 28, 2017  Today, ... Pharmacy released a new white paper to ... use of latex in healthcare. Specifically, there is substantial confusion ... fact, the FDA has urged manufacturers to drop the term ... labels, because of the challenge to ensure a product is ...
(Date:3/28/2017)... ALBANY, New York , March 28, 2017 /PRNewswire/ ... features a largely consolidated vendor landscape, with the top ... and Agilent Technologies accounting for a significant 49% of ... in a recent report. The vendor landscape is intensely ... large share in the overall market. These factors have ...
(Date:3/28/2017)...  Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: ... directors: Christopher Gabrieli , ... as chairman of the board of Akcea Therapeutics. ... Forest Laboratories. Sandford D. Smith , ... "We are excited to announce this expansion to our ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, the leading ... of a free, public-facing tool for analyzing the costs of various drug regimens ... comparative information to patients, providers, insurers and pharmaceutical companies about the estimated costs ...
(Date:3/28/2017)... ... ... WHO: , Dr. Paul Thomas; Dr. Brian Hooker; Dr. Judy Mikovits; Dr. Jennifer ... speak to the press on behalf of over 200 doctors, scientists, and scientific organizations ... , WHERE: , Zenger Room, National Press Club, 529 14th Street NW, 13th ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... are critical to ensuring high-quality results and maintaining GMP and USP compliance. In ... Instruments in accordance with GMP requirements " these requirements are explained. The ...
(Date:3/28/2017)... ... 2017 , ... Neurotechnology , a provider of high-precision ... tracking products: the new NCheck Cloud Bio Attendance cloud-based service and the updated  ... recognition to enable users to check in and out from anywhere via the ...
(Date:3/28/2017)... WI (PRWEB) , ... March 28, 2017 , ... ... self-funded health plans work, the Self-Funding Success website has recently developed and published ... Self-Funded Health Plans ” was created based on common inquiries the site’s team ...
Breaking Medicine News(10 mins):